What is giritinib (segatan) and its main clinical uses?

Gilitinib (Gilteritinib) is a new type of targeted anti-cancer drug. It is an oral small molecule tyrosine kinase inhibitor that mainly targetsFMS-like tyrosine kinaseAML) mutated in >3(FLT3). FLT3mutations are common in AML patients, especially internal tandem duplications (ITD) and point mutations (TKD), which can lead to abnormal proliferation of leukemia cells and disease progression. Giritinib exerts anti-tumor effects by selectively inhibiting the FLT3 signaling pathway to prevent the growth and spread of leukemia cells.

In terms of clinical application, giritinib is mainly used to treat relapsed or refractory AML patients with FLT3 mutations. Traditional chemotherapy regimens have limited efficacy and poor prognosis for these patients, and giritinib, as a targeted therapy, provides them with a new treatment option. Clinical studies have shown that giritinib can significantly improve the response rate and survival time of patients. Compared with traditional chemotherapy, its efficacy is more outstanding and it is better tolerated.

The use of giritinib is not only suitable for monotherapy, but can also be used in combination with other chemotherapy drugs or targeted drugs to enhance the efficacy. In the combination regimen, giritinib can synergize with chemotherapy drugs to improve the complete response rate (CR) and overall response rate (ORR), while delaying disease recurrence. This flexible dosing strategy makes giritinib have important clinical value in the treatment of AML.

In general, giritinib is a precisely targeted drug targeting specific gene mutations and is mainly used for the treatment of patients with relapsed or refractory AML. Its clinical advantages include significantly improved response rates, prolonged survival, and good tolerability. With the accumulation of more real-world studies and clinical data, giritinib is expected to have wider application value in personalized treatment plans for AML patients.

Reference materials:https://www.drugs.com/